Abstract:Objective To investigate the clinical effect of Magnesium Valproate Sustained Release Tablets combined with Olanzapine in the treatment of Alzheimer′s disease.Methods A total of 80 patients in our hospital from October 2015 to October 2017 were selected and divided into the treatment group and the control group by stratified sampling,40 cases in each group.The patients in the treatment group were treated with Magnesium Valproate Sustained Release Tablets and Olanzapine,while the control group was treated with Olanzapine only.After four weeks of treatment,the behavior and consciousness were evaluated by BRMS,and the SF-36 scale evaluated the quality of life.The difference between the manic state and the quality of life in the two groups was analyzed.Results After 4 weeks of treatment,the treatment group of patients with mania was significantly lower than that of the control group(P<0.05),quality of life include physical function in treatment group patients,social function,activity,psychological function was significantly higher than that in the control group,the differences were statistically significant(P<0.05).Conclusion Magnesium Valproate Sustained Release Tablets combined with Olanzapine are able to control the behavioral and psychological symptoms of Alzheimer′s disease more quickly and effectively.It is suggested that to be promoted in clinical work.
林彩云; 蔡齐健; 卢仪. 丙戊酸镁缓释片联合奥氮平治疗阿尔茨海默病患者的临床效果[J]. 中国当代医药, 2018, 25(13): 163-165.
LIN Cai-yun; CAI Qi-jian ;LU Yi. The clinical effect of Magnesium Valproate Sustained Release Tablets combined with Olanzapine in the treatment of Alzheimer′s disease. 中国当代医药, 2018, 25(13): 163-165.
Tomasik J,Schwarz E,Lago SG,et al.Pretreatment levels of the fatty acid handling proteins H-FABP and CD36 predict response to olanzapine in recent-onset schizophrenia patients[J].Brain Behav Immun,2016,52:178-186.
[12]
Graipaspong N,Thaipisuttikul P,Vallipakorn SA.Cholinesterase inhibitors and behavioral&psychological symptoms of alzheimer′s disease[J].J Med Assoc Thai,2016,99(4):433-440.